Evidence map›Paper›PMID 20083897›Full record

ArticlePrion

New insights into the molecular mechanism of amyloid formation from cysteine scanning.

Li Fei, Sarah Perrett

Abstract read
In one paragraph

Article in Prion. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Li FeiNational Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. sarah.perrett@cantab.net
Sarah Perrett

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our laboratory recently reported the identification of a peptide region, QVNI, within the prion domain of the yeast protein Ure2 that may act as an initiation point for fibril formation.(1) This potential amyloid-forming region, which corresponds to residues 18-21 of Ure2, was initially identified by systematic cysteine scanning of the Ure2 prion domain. The point mutant R17C, and the corresponding octapeptide CQVNIGNR, were found to form fibrils rapidly under oxidative conditions due to the formation of a disulfide bond. Deletions within the QVNI sequence cause the fibril formation ability of R17C Ure2 to be inhibited. The aggregation propensity of this region is strongly modulated by its preceding residue: replacement of R17 with a hydrophobic residue promotes fibril formation in both full-length Ure2 and in the corresponding octapeptides. The wild-type octapeptide, RQVNIGNR, also forms fibrils, and is the shortest amyloid-forming peptide found for Ure2 to date. Interestingly, the wild-type octapeptide crystallizes readily and so provides a starting point towards obtaining high resolution structural information for the amyloid core of Ure2 fibrils.

Indexed as

Amino Acid SequenceAmyloidCysteineGlutathione PeroxidaseHumansMolecular Sequence DataPrionsSaccharomyces cerevisiae ProteinsAmyloidCysteineGlutathione PeroxidasePrionsSaccharomyces cerevisiae ProteinsURE2 protein, S cerevisiae

Identifiers

PMID20083897
PMCPMC2850414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.